Comparing Randomized Controlled Trials and Real-World Studies in Chronic Obstructive Pulmonary Disease Pharmacotherapy

References

• Centers for Disease Control and Prevention. Descriptive and analytic studies; 2012 Available from: https://www.cdc.gov/globalhealth/healthprotection/fetp/training_modules/19/desc-and-analytic-studies_ppt_final_09252013.pdf. Accessed 226, 2019.
   Google Scholar
• ZuidgeestMGP, GoetzI, GroenwoldRHH, IrvingE, van ThielGJMW, GrobbeeDE. Series: pragmatic trials and real world evidence: paper 1. Introduction. J Clin Epidemiol. 2017;88:7–13. doi:10.1016/j.jclinepi.2016.12.02328549929
   PubMed Web of Science ®Google Scholar
• ClancyMJ. Overview of research designs. Emerg Med J. 2002;19(6):546–549. doi:10.1136/emj.19.6.54612421782
   PubMed Web of Science ®Google Scholar
• GrimesDA, SchulzKF. An overview of clinical research: the lay of the land. Lancet (London, England). 2002;359(9300):57–61. doi:10.1016/S0140-6736(02)07283-5
   PubMed Web of Science ®Google Scholar
• U.S._Department_of_Health_and_Human_Services_Centers_for_Disease_Control_and_Prevention_CDC. Principles of Epidemiology in Public Health Practice. An Introduction to Applied Epidemiology and Biostatistics. 3 ed. U.S. Department of Health and Human Services_Centers for Disease Control and Prevention (CDC); 2012 Available from: https://www.cdc.gov/ophss/csels/dsepd/ss1978/SS1978.pdf. Accessed 1212, 2018.
   Google Scholar
• MannCJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J. 2003;20(1):54–60. doi:10.1136/emj.20.1.5412533370
   PubMed Web of Science ®Google Scholar
• SackettDL. Explanatory and pragmatic clinical trials: a primer and application to a recent asthma trial. Pol Arch Med Wewn. 2011;121(7–8):259–263.21878863
   PubMed Web of Science ®Google Scholar
• U.S._Department_of_Health_and_Human_Services_Food_and_Drug_Administration. The drug development process 2018. Available from: https://www.fda.gov/ForPatients/Approvals/Drugs/default.htm. Accessed 57, 2020.
   Google Scholar
• United States Food and Drug Administration. Inside clinical trials: testing medical products in people; 2014 Available from: https://www.fda.gov/drugs/drug-information-consumers/inside-clinical-trials-testing-medical-products-people. Accessed 312, 2020.
   Google Scholar
• HillTP. Conducting phase IV clinical studies: a moral imperative? ecancermedicalscience. 2012;6:276. doi:10.3332/ecancer.2012.276
   Google Scholar
• HaqueA, DanielS, MaxwellT, BoerstoelM. Postmarketing surveillance studies-an industry perspective on changing global requirements and implications. Clin Ther. 2017;39(4):675–685. doi:10.1016/j.clinthera.2017.03.01128392076
   PubMed Web of Science ®Google Scholar
• SuvarnaV. Phase IV of drug development. Perspect Clin Res. 2010;1(2):57–60.21829783
   PubMedGoogle Scholar
• ZhangX, ZhangY, YeX, GuoX, ZhangT, HeJ. Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.gov registry. BMJ Open. 2016;6(11):e010643. doi:10.1136/bmjopen-2015-010643
   PubMed Web of Science ®Google Scholar
• U.S._Department_of_Health_and_Human_Services_Food_and_Drug_Administration. Guidance for industry expedited programs for serious conditions – drugs and biologics 2014. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf. Accessed 57, 2020.
   Google Scholar
• United States Food and Drug Administration. Non-inferiority clinical trials to establish effectiveness: guidance for industry 2016. Available from: https://www.fda.gov/downloads/Drugs/Guidances/UCM202140.pdf. Accessed 3 14, 2019.
   Google Scholar
• PeduzziP, HendersonW, HartiganP, LavoriP. Analysis of randomized controlled trials. Epidemiol Rev. 2002;24(1):26–38. doi:10.1093/epirev/24.1.2612119853
   PubMed Web of Science ®Google Scholar
• ErikssonG, CalverleyPM, JenkinsCR, et al. The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials. Int J Chron Obstruct Pulmon Dis. 2017;12:1457–1468. doi:10.2147/COPD.S13071328553098
   PubMed Web of Science ®Google Scholar
• SayreJW, TokluHZ, YeF, MazzaJ, YaleS. Case reports, case series - from clinical practice to evidence-based medicine in graduate medical education. Cureus. 2017;9(8):e1546. doi:10.7759/cureus.154629018643
   PubMed Web of Science ®Google Scholar
• GarrisonLP Jr., NeumannPJ, EricksonP, MarshallD, MullinsCD. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health. 2007;10(5):326–335. doi:10.1111/j.1524-4733.2007.00186.x17888097
   PubMed Web of Science ®Google Scholar
• BlandJM, AltmanDG. Statistics notes: matching. BMJ (Clinical Research Ed). 1994;309(6962):1128. doi:10.1136/bmj.309.6962.1128
   PubMed Web of Science ®Google Scholar
• TunisSR, StryerDB, ClancyCM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290(12):1624–1632. doi:10.1001/jama.290.12.162414506122
   PubMed Web of Science ®Google Scholar
• GamermanV, CaiT, ElsäßerA. Pragmatic randomized clinical trials: best practices and statistical guidance. Health Serv Outcomes Res Methodol. 2018;19:23–25. doi:10.1007/s10742-018-0192-5
   Web of Science ®Google Scholar
• WoodcockA, BakerlyND, NewJP, et al. The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma. BMC Pulm Med. 2015;15:160. doi:10.1186/s12890-015-0150-826651333
   PubMed Web of Science ®Google Scholar
• CollinsR, BowmanL, LandrayM, PetoR. The magic of randomization versus the myth of real-world evidence. N Engl J Med. 2020;382(7):674–678. doi:10.1056/NEJMsb190164232053307
   PubMed Web of Science ®Google Scholar
• AndersonML, GriffinJ, GoldkindSF, et al. The Food and Drug Administration and pragmatic clinical trials of marketed medical products. Clin Trials. 2015;12(5):511–519. doi:10.1177/174077451559770026374684
   PubMed Web of Science ®Google Scholar
• LoudonK, TreweekS, SullivanF, DonnanP, ThorpeKE, ZwarensteinM. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ (Clinical Research Ed). 2015;350:h2147. doi:10.1136/bmj.h2147
   PubMed Web of Science ®Google Scholar
• GobleJA. The potential effect of the 21st Century Cures Act on drug development. J Manag Care Spec Pharm. 2018;24(7):677–681. doi:10.18553/jmcp.2018.24.7.67729952706
   PubMed Web of Science ®Google Scholar
• BueschingDP, LuceBR, BergerML. The role of private industry in pragmatic comparative effectiveness trials. J Comp Eff Res. 2012;1(2):147–156. doi:10.2217/cer.12.924237375
   PubMed Web of Science ®Google Scholar
• BogartM, StanfordRH, LaliberteF, GermainG, WuJW, DuhMS. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis. 2019;14:343–352. doi:10.2147/COPD.S18465330863037
   PubMed Web of Science ®Google Scholar
• HwangIK, MorikawaT. Design issues in noninferiority/equivalence trials. Drug Inf J. 1999;33(4):1205–1218. doi:10.1177/009286159903300424
   Google Scholar
• PatsopoulosNA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci. 2011;13(2):217–224.21842619
   PubMedGoogle Scholar
• MollerHJ. Effectiveness studies: advantages and disadvantages. Dialogues Clin Neurosci. 2011;13(2):199–207.21842617
   PubMedGoogle Scholar
• AlthunianTA, de BoerA, GroenwoldRHH, KlungelOH. Defining the noninferiority margin and analysing noninferiority: an overview. Br J Clin Pharmacol. 2017;83(8):1636–1642. doi:10.1111/bcp.1328028252213
   PubMed Web of Science ®Google Scholar
• SchumiJ, WittesJT. Through the looking glass: understanding non-inferiority. Trials. 2011;12:106. doi:10.1186/1745-6215-12-10621539749
   PubMed Web of Science ®Google Scholar
• JonesB, JarvisP, LewisJA, EbbuttAF. Trials to assess equivalence: the importance of rigorous methods. BMJ (Clinical Research Ed). 1996;313(7048):36–39. doi:10.1136/bmj.313.7048.36
   PubMed Web of Science ®Google Scholar
• Patient-Centered Outcomes Research Institute. PCORI dissemination & implementation framework. Available from: https://www.pcori.org/sites/default/files/PCORI-Dissemination-Implementation-Framework.pdf. Accessed 39, 2020.
   Google Scholar
• National Heart, Lung, and Blood Institute Strategic Visioning. Setting an agenda together for the NHLBI of 2025. Available from: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.115.015712. Accessed 39, 2020.
   Google Scholar
• ElmesPC, FletcherCM, DuttonAA. Prophylactic use of oxytetracycline for exacerbations of chronic bronchitis. Br Med J. 1957;2(5056):1272–1275. doi:10.1136/bmj.2.5056.127213479695
   PubMed Web of Science ®Google Scholar
• MayJR, OswaldNC. Long-term chemotherapy in chronic bronchitis. Lancet (London, England). 1956;271(6947):814–818. doi:10.1016/s0140-6736(56)92245-0
   PubMedGoogle Scholar
• VinckenW, van NoordJA, GreefhorstAP, et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J. 2002;19(2):209–216. doi:10.1183/09031936.02.0023870211871363
   PubMed Web of Science ®Google Scholar
• AnthonisenNR, ManfredaJ, WarrenCP, HershfieldES, HardingGK, NelsonNA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196–204. doi:10.7326/0003-4819-106-2-1963492164
   PubMed Web of Science ®Google Scholar
• AlbertRK, ConnettJ, BaileyWC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698. doi:10.1056/NEJMoa110462321864166
   PubMed Web of Science ®Google Scholar
• NonoyamaML, BrooksD, GuyattGH, GoldsteinRS. Effect of oxygen on health quality of life in patients with chronic obstructive pulmonary disease with transient exertional hypoxemia. Am J Respir Crit Care Med. 2007;176(4):343–349. doi:10.1164/rccm.200702-308OC17446339
   PubMed Web of Science ®Google Scholar
• Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93(3):391–398. doi:10.7326/0003-4819-93-3-3916776858
   PubMed Web of Science ®Google Scholar
• Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet (London, England). 1981;1(8222):681–686. Available from: https://pubmed.ncbi.nlm.nih.gov/6110912/
   PubMed Web of Science ®Google Scholar
• AlbertRK, AuDH, et al.; Long-Term_Oxygen_Treatment_Trial_Research_Group. A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med. 2016;375(17):1617–1627. doi:10.1056/NEJMoa160434427783918
   PubMed Web of Science ®Google Scholar
• Pearl Therapeutics Inc. Study to assess the efficacy and safety of PT010 relative to PT003 and PT009 in subjects with moderate to very severe COPD (Ethos); 2015 Available from: https://clinicaltrials.gov/ct2/show/NCT2465567. Accessed 1203, 2018.
   Google Scholar
• NiewoehnerDE, RiceK, CoteC, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143(5):317–326. doi:10.7326/0003-4819-143-5-200509060-0000716144890
   PubMed Web of Science ®Google Scholar
• TashkinDP, CelliB, SennS, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa080580018836213
   PubMed Web of Science ®Google Scholar
• GrossNJ. Ipratropium bromide. N Engl J Med. 1988;319(8):486–494. doi:10.1056/NEJM1988082531908062970009
   PubMed Web of Science ®Google Scholar
• HaddadEB, MakJC, BarnesPJ. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol. 1994;45(5):899–907.8190106
   PubMed Web of Science ®Google Scholar
• DisseB, ReichlR, SpeckG, TrauneckerW, Ludwig RomingerKL, HammerR. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 1993;52(5–6):537–544. doi:10.1016/0024-3205(93)90312-Q8441333
   PubMed Web of Science ®Google Scholar
• TakahashiT, BelvisiMG, PatelH, et al. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med. 1994;150(6 Pt 1):1640–1645. doi:10.1164/ajrccm.150.6.79526277952627
   PubMed Web of Science ®Google Scholar
• MaesenFP, SmeetsJJ, CostongsMA, WaldFD, CornelissenPJ. Ba 679 Br, a new long-acting antimuscarinic bronchodilator: a pilot dose-escalation study in COPD. Eur Respir J. 1993;6(7):1031–1036.8370429
   PubMed Web of Science ®Google Scholar
• LittnerMR, IlowiteJS, TashkinDP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1136–1142. doi:10.1164/ajrccm.161.4.990304410764302
   PubMed Web of Science ®Google Scholar
• van NoordJA, BantjeTA, ElandME, KorduckiL, CornelissenPJ. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax. 2000;55(4):289–294. doi:10.1136/thorax.55.4.28910722768
   PubMed Web of Science ®Google Scholar
• CaillaudD, Le MerreC, MartinatY, AguilaniuB, PaviaD. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or Handihaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2007;2(4):559–565.18268929
   PubMedGoogle Scholar
• van NoordJA, CornelissenPJ, AumannJL, PlatzJ, MuellerA, FogartyC. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med. 2009;103(1):22–29. doi:10.1016/j.rmed.2008.10.00219022642
   PubMed Web of Science ®Google Scholar
• BatemanE, SinghD, SmithD, et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis. 2010;5:197–208.20714373
   PubMedGoogle Scholar
• BatemanED, TashkinD, SiafakasN, et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med. 2010;104(10):1460–1472. doi:10.1016/j.rmed.2010.06.00420620037
   PubMed Web of Science ®Google Scholar
• WiseRA, AnzuetoA, CottonD, et al. Tiotropium Respimat Inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–1501. doi:10.1056/NEJMoa130334223992515
   PubMed Web of Science ®Google Scholar
• BundschuhDS, EltzeM, BarsigJ, WollinL, HatzelmannA, BeumeR. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther. 2001;297(1):280–290.11259555
   PubMed Web of Science ®Google Scholar
• WollinL, BundschuhDS, WohlsenA, MarxD, BeumeR. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. Pulm Pharmacol Ther. 2006;19(5):343–352. doi:10.1016/j.pupt.2005.09.00216257550
   PubMed Web of Science ®Google Scholar
• DavidM, ZechK, SeiberlingM, WeimarC, BethkeT. Roflumilast, a novel, oral, selective PDE4 inhibitor, shows high absolute bioavailability. J Allergy Clin Immunol Immunol. 2004;113(2):S220–S221. doi:10.1016/j.jaci.2004.01.246
   Google Scholar
• GrootendorstDC, GauwSA, VerhooselRM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007;62(12):1081–1087. doi:10.1136/thx.2006.07593717573446
   PubMed Web of Science ®Google Scholar
• RabeKF, BatemanED, O’DonnellD, WitteS, BredenbrokerD, BethkeTD. Roflumilast–an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (London, England). 2005;366(9485):563–571. doi:10.1016/S0140-6736(05)67100-0
   PubMed Web of Science ®Google Scholar
• CalverleyPM, Sanchez-TorilF, McIvorA, TeichmannP, BredenbroekerD, FabbriLM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(2):154–161. doi:10.1164/rccm.200610-1563OC17463412
   PubMed Web of Science ®Google Scholar
• RennardSI, CalverleyPM, GoehringUM, BredenbrokerD, MartinezFJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18. doi:10.1186/1465-9921-12-1821272339
   PubMed Web of Science ®Google Scholar
• CalverleyPM, RabeKF, GoehringUM, KristiansenS, FabbriLM, MartinezFJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet (London, England). 2009;374(9691):685–694. doi:10.1016/S0140-6736(09)61255-1
   PubMed Web of Science ®Google Scholar
• MartinezFJ, CalverleyPM, GoehringUM, BroseM, FabbriLM, RabeKF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet (London, England). 2015;385(9971):857–866. doi:10.1016/S0140-6736(14)62410-7
   PubMed Web of Science ®Google Scholar
• MartinezFJ, RabeKF, SethiS, et al. Effect of roflumilast and inhaled corticosteroid/long-acting beta2-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial. Am J Respir Crit Care Med. 2016;194(5):559–567. doi:10.1164/rccm.201607-1349OC27585384
   PubMed Web of Science ®Google Scholar
• ChapmanKR, HurstJR, FrentSM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–339. doi:10.1164/rccm.201803-0405OC29779416
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnhartF, BrealeyN, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa171390129668352
   PubMed Web of Science ®Google Scholar
• SinghD, PapiA, CorradiM, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet (London, England). 2016;388(10048):963–973. doi:10.1016/S0140-6736(16)31354-X
   PubMed Web of Science ®Google Scholar
• FergusonGT, RabeKF, MartinezFJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. doi:10.1016/S2213-2600(18)30327-830232048
   PubMed Web of Science ®Google Scholar
• MagnussenH, DisseB, Rodriguez-RoisinR, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294. doi:10.1056/NEJMoa140715425196117
   PubMed Web of Science ®Google Scholar
• WatzH, TetzlaffK, WoutersEF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–398. doi:10.1016/S2213-2600(16)00100-427066739
   PubMed Web of Science ®Google Scholar
• VestboJ, PapiA, CorradiM, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet (London, England). 2017;389(10082):1919–1929. doi:10.1016/S0140-6736(17)30188-5
   PubMed Web of Science ®Google Scholar
• PapiA, VestboJ, FabbriL, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet (London, England). 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X
   PubMed Web of Science ®Google Scholar
• VogelmeierC, WorthH, BuhlR, et al. “Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. Int J Chron Obstruct Pulmon Dis. 2017;12:487–494. doi:10.2147/COPD.S12561628203072
   PubMed Web of Science ®Google Scholar
• BakerlyND, WoodcockA, NewJP, et al. The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease. Respir Res. 2015;16:101. doi:10.1186/s12931-015-0267-626337978
   PubMed Web of Science ®Google Scholar
• VestboJ, LeatherD, Diar BakerlyN, et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med. 2016;375(13):1253–1260. doi:10.1056/NEJMoa160803327593504
   PubMed Web of Science ®Google Scholar
• Girodet P-O, Raherison C, Molimard M. Effectiveness of fluticasone furoate–vilanterol in COPD. N Engl J Med. 2016;375(26):2605–2607. doi:10.1056/NEJMc1613713
   Google Scholar
• Dal-ReR. Could phase 3 medicine trials be tagged as pragmatic? A case study: the Salford COPD trial. J Eval Clin Pract. 2018;24(1):258–261. doi:10.1111/jep.1279628685913
   PubMed Web of Science ®Google Scholar
• Boehringer_Ingelheim. The AIRWISE study: assessment in a real world setting of the effect of inhaled steroid-based triple therapy versus the combination of tiotropium and olodaterol on reducing chronic obstructive pulmonary disease (COPD) exacerbations [AIRWISE]; August 2017 [updated December 2017] Available from: https://clinicaltrials.gov/ct2/show/NCT3265145. Accessed 1 2018.
   Google Scholar
• National Institutes of Health U.S. National Library of Medicine. Roflumilast or azithromycin to prevent COPD exacerbations (RELIANCE) (RELIANCE; NCT4069312). Available from: https://clinicaltrials.gov/ct2/show/NCT4069312. Accessed 39, 2020.
   Google Scholar
• KimHS, LeeS, KimJH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018;33(34):e213. doi:10.3346/jkms.2018.33.e21330127705
   PubMed Web of Science ®Google Scholar
• SinghD, FergusonGT, BolitschekJ, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312–1319. doi:10.1016/j.rmed.2015.08.00226320402
   PubMed Web of Science ®Google Scholar
• CalverleyPMA, AnzuetoAR, CarterK, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337–344. doi:10.1016/S2213-2600(18)30102-429605624
   PubMed Web of Science ®Google Scholar
• WedzichaJA, ZhongN, IchinoseM, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. Int J Chron Obstruct Pulmon Dis. 2017;12:339–349. doi:10.2147/COPD.S12505828176893
   PubMed Web of Science ®Google Scholar
• RossiA, GuerrieroM, CorradoA. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res. 2014;15:77. doi:10.1186/1465-9921-15-7725005873
   PubMed Web of Science ®Google Scholar
• SampJC, JooMJ, SchumockGT, CalipGS, PickardAS, LeeTA. Comparative effectiveness of long-acting beta2 -agonist combined with a long-acting muscarinic antagonist or inhaled corticosteroid in chronic obstructive pulmonary disease. Pharmacotherapy. 2017;37(4):447–455. doi:10.1002/phar.191328226405
   PubMed Web of Science ®Google Scholar
• VoorhamJ, KerkhofM, ScuriM, et al. Late breaking abstract - comparative real world effectiveness of triple therapy versus dual bronchodilation in frequently exacerbating patients with COPD. Eur Respir J. 2018;52(suppl 62). doi:10.1183/13993003.01675-2018
   Web of Science ®Google Scholar
• PriceDB, GefenE, GopalanG, et al. Real-life effectiveness and safety of salbutamol Steri-Neb vs. Ventolin Nebules(R) for exacerbations in patients with COPD: historical cohort study. PLoS One. 2018;13(1):e0191404. doi:10.1371/journal.pone.019140429364929
   PubMed Web of Science ®Google Scholar
• NybergA, WadellK, LindgrenH, TistadM. Internet-based support for self-management strategies for people with COPD-protocol for a controlled pragmatic pilot trial of effectiveness and a process evaluation in primary healthcare. BMJ Open. 2017;7(7):e016851. doi:10.1136/bmjopen-2017-016851
   PubMed Web of Science ®Google Scholar
• VogelmeierCF, GagaM, Aalamian-MattheisM, et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res. 2017;18(1):140. doi:10.1186/s12931-017-0622-x28720132
   PubMed Web of Science ®Google Scholar
• BergerML, SoxH, WillkeRJ, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Value Health. 2017;20(8):1003–1008. doi:10.1016/j.jval.2017.08.301928964430
   PubMed Web of Science ®Google Scholar
• SingalAG, HigginsPD, WaljeeAK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014;5:e45. doi:10.1038/ctg.2013.1324384867
   PubMed Web of Science ®Google Scholar
• RossiA, van der MolenT, Del OlmoR, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44(6):1548–1556. doi:10.1183/09031936.0012681425359348
   PubMed Web of Science ®Google Scholar